Seoul, South Korea, January 25, 2023 /PRNewswire/ — GenKOre, Inc., a Korea-based biotech company with hyper-compact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharmaceutical company to develop empathize gene editing therapies. This collaboration leverages GenKOre’s proprietary CRISPR-Cas platform, TaRGET (Tiny nuclease, aenlarge RNA-based Genough Editen Ttechnology). The TaRGET platform differs from the most popular genome editing technology, CRISPR-Cas9, in that the entire editing module can be delivered with a single AAV vector. Based on their TaRGET platform, GenKOre has developed various modalities of editing tools, including TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI (Gene Activation and Inhibition system). and TARGET FREE (Gene knock-in).
“This collaboration reflects the strength and potential utility of the TaRGET platform in the application of empathize gene editing therapy,” said Yongsam Kim, CEO of GenKOre. “This collaboration not only offers the opportunity to validate the applicability of the TaRGET platform empathize therapy, but we will also extend the utility of our technologies to a broader spectrum of rare diseases.” The collaboration was based on the mutual interest in forging transformative therapies for patients with rare diseases.
Under the terms of the agreement, GenKOre will receive up to USD 300 million, including upfront payments, option exercise fees and milestone payments upon successful achievement of R&D and commercial milestones in two empathize disease targets. In addition, GenKOre receives research funding and tiered royalties up to a double-digit percentage of net sales.